Navigation Links
Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger
Date:11/23/2009

SOUTH SAN FRANCISCO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that Dr. Ted W. Love and Dr. David C. U'Prichard have agreed to join the Anesiva board of directors following completion of the proposed merger between Anesiva and Arcion Therapeutics. Completion of the merger is subject to a shareholder vote scheduled to take place at the previously announced Anesiva 2009 Annual Meeting of Stockholders, to be held on December 3, 2009 at 9:00 a.m. PST at 400 Oyster Point, Suite 107A, South San Francisco, California, among other conditions.

"We are very pleased to be able to recruit directors of this caliber. Their talents will be important as we make plans to move our new company forward after the merger," said Michael Kranda, president and chief executive officer of Anesiva.

"Maintaining governance requirements and a qualified NASDAQ listing is a high priority for the merged companies and these gentlemen will bring excellent experience to our board," said Dr. Arnold Oronsky, director of Anesiva and Arcion Therapeutics.

From 2001 to 2009, Dr. Love served as president, chief executive officer and director of Nuvelo, Inc., a biopharmaceutical company, and as chairman of the company's board of directors from 2005 to 2009, prior to its merger with ARCA Biopharma, Inc. From 1998 to 2001, Dr. Love served as senior vice president of development at Theravance, Inc. (formerly Advanced Medicine, Inc.). From 1992 to 1998, Dr. Love served as a research physician and vice president of product development at Genentech, Inc. Dr. Love also serves as member of the board of directors of Santarus, ARCA and Affymax. Dr. Love holds an M.D. from Yale medical school and a B.A. from Haverford College.

Dr. U'Prichard currently serves as president of Druid Consulting LLC and as a venture partner at Red Abbey Venture Partners. Previously, he was chief executive officer of 3-Dimensional Pharmaceuticals (3DP) from 1999 to 2003. From 1997 to 1999, Dr. U'Prichard served as chairman of research and development at SmithKline Beecham Pharmaceuticals. Prior to SmithKline Beecham, he worked for ICI/Zeneca from 1986 to 1997, as executive vice president and International Research Director from 1994 to 1997. He is currently a member of the board of directors of Life Technologies and Silence Therapeutics Plc, and chairman of Cyclacel, Inc. and Oxagen Ltd. Dr. U'Prichard received his Ph.D. from the University of Kansas and his B.Sc. from the University of Glasgow, Scotland.

About Anesiva

Anesiva seeks to be a leader in the development and commercialization of novel pharmaceutical products for pain management. Anesiva's lead product candidate is Adlea, a novel small molecule formulation of capsaicin that is currently in development for the management of acute pain following orthopedic surgeries. Adlea has been shown in clinical trials to provide extended pain relief after only a single administration in multiple indications for site-specific, acute and chronic, moderate-to-severe pain.

About Arcion

Arcion Therapeutics applies breakthroughs in neuroscience to advance the treatment of chronic pain. The company focuses on innovative topical treatments to provide pain relief with convenient application and reduced systemic side effects. Arcion's product pipeline comprises multiple candidates to treat neuropathic pain.

Additional Information and Where to Find It

Anesiva has a filed a definitive proxy statement with the Securities and Exchange Commission (the "SEC") in connection with the 2009 Annual Meeting of Stockholders. Investors and security holders are urged to read the definitive proxy statement because it contains important information about the 2009 Annual Meeting of Stockholders. Investors and security holders may obtain free copies of this document and other documents filed with the SEC at the SEC's website at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by Anesiva by contacting John Tran at 650-624-9600.

Anesiva and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Anesiva in connection with the 2009 Annual Meeting of Stockholders. Information regarding the special interests of these directors and executive officers is included in the definitive proxy statement of Anesiva described above. Additional information regarding the directors and executive officers of Anesiva is also included in Anesiva's Annual Report on Form 10-K, which was filed with the SEC on March 25, 2009, and in any documents subsequently filed by the directors and executive officers under the Securities Exchange Act of 1934, as amended.

Forward-Looking Statements

Except for historical information, this press release may be deemed to contain "forward-looking" statements. Words such as "seek," "will," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include statements regarding expectations as to forecasts of product development and other matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. The forward-looking statements contained herein involve risks and uncertainties that could cause actual results to differ materially from those referred to in the forward-looking statements. Such risks include, but are not limited to, the risk of whether certain market segments grow as anticipated; clinical trial results; the competitive environment in the biotechnology industry; and whether the Anesiva can successfully develop new products and the degree to which these gain market acceptance as well as other risks detailed from time to time in Anesiva's filings with the Securities and Exchange Commission (the "SEC"), including Anesiva's most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2008, its Quarterly Reports on Form 10-Q and its Current Reports on Form 8-K as filed with the SEC. Anesiva expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

SOURCE Anesiva, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
2. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
3. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
4. Anesiva Defines Regulatory Pathway for Adlea with FDA
5. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
6. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
7. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
8. Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
9. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
10. Anesiva Commences Phase 2 Trial of Adlea(TM) in Arthroscopic Shoulder Surgery
11. Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 24, 2016 Open Access Journal ... Neurophysiology  Elsevier , a world-leading provider ... today announced the launch of Clinical Neurophysiology ... that focuses on clinical practice issues in clinical neurophysiology. ... series, normal values and didactic reviews. It is an ...
(Date:5/23/2016)... 23, 2016 According to ... Market by Product (Wheelchair, Scooters, Medical Beds, Bathroom ... Critical Care, Wound), Accessories (Lifting, Transfer) & by ... published by MarketsandMarkets, the patient handling equipment market ... 2021 at a CAGR of 10.5% during the ...
(Date:5/23/2016)... Transparency Market Research has published ... Market - Global Industry Analysis, Size, Share, Growth, Trends, ... report, the exocrine pancreatic insufficiency market is anticipated to ... 2023 to reach US$2.85 Bn by 2023. ... the deficiency of the exocrine pancreatic enzymes, causing failure ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... ... has seen a significant spike in their clients' employee participation for their wellness ... health screening by implementing a high-deductible health plan with outcome-based deductible incentives. As ...
(Date:5/25/2016)... ... ... Stern Environmental Group , of Secaucus, New Jersey, working in conjunction ... Real Time Monitoring (RTM) Device. Stern Environmental Group will sell the first monitoring ... use in dormitories, shelters, and nursing homes for real time bedbug monitoring in May ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... (Rudy) Cifolelli has joined the company as Vice President of Sales. Cifolelli’s ... U.S. and international sales in the rapidly expanding field of organizational social engineering. ...
(Date:5/24/2016)... ... ... Jericho Project has named LaToya Williams-Belfort to the position of Chief Development and ... for the nationally-acclaimed nonprofit, working closely with CEO Tori Lyon and the Board of ... roots. , “LaToya Williams-Belfort is joining Jericho at an exciting time of growth ...
(Date:5/24/2016)... ... , ... How to Write Error Free Procedures, **Presented by Ginette M. Collazo ... is known to be the major cause of quality and production losses in many ... human performance problems can be prevented. , How to Write Error Free Procedures, part ...
Breaking Medicine News(10 mins):